Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Times Interest Earned (2016 - 2025)

Historic Times Interest Earned for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $2.02.

  • Zevra Therapeutics' Times Interest Earned rose 11710.33% to $2.02 in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.66, marking a year-over-year increase of 2732.1%. This contributed to the annual value of -$11.84 for FY2024, which is 6418.61% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Times Interest Earned of $2.02 as of Q3 2025, which was up 11710.33% from -$35.36 recorded in Q2 2025.
  • In the past 5 years, Zevra Therapeutics' Times Interest Earned ranged from a high of $364.56 in Q2 2021 and a low of -$689.31 during Q2 2022
  • Its 5-year average for Times Interest Earned is -$103.52, with a median of -$31.74 in 2023.
  • The largest annual percentage gain for Zevra Therapeutics' Times Interest Earned in the last 5 years was 1672920.6% (2021), contrasted with its biggest fall of 3540681.51% (2021).
  • Over the past 5 years, Zevra Therapeutics' Times Interest Earned (Quarter) stood at -$568.4 in 2021, then skyrocketed by 90.54% to -$53.78 in 2022, then soared by 62.72% to -$20.05 in 2023, then surged by 64.95% to -$7.03 in 2024, then soared by 128.75% to $2.02 in 2025.
  • Its last three reported values are $2.02 in Q3 2025, -$35.36 for Q2 2025, and -$2.72 during Q1 2025.